Total Payments
$437,610
2024 Payments
$13,684
Companies
27
Transactions
1,021
Medicare Patients
1,163
Medicare Billing
$189,610
Payment Breakdown by Category
Other$382,374 (87.4%)
Travel$28,260 (6.5%)
Food & Beverage$20,250 (4.6%)
Consulting$6,593 (1.5%)
Education$73.44 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $373,799 | 272 | 85.4% |
| Travel and Lodging | $28,260 | 197 | 6.5% |
| Food and Beverage | $20,250 | 531 | 4.6% |
| Honoraria | $8,575 | 6 | 2.0% |
| Consulting Fee | $6,593 | 7 | 1.5% |
| Education | $73.44 | 7 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $214,288 | 394 | $0 (2023) |
| Novo Nordisk Inc | $156,171 | 279 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33,332 | 73 | $0 (2021) |
| Dexcom, Inc. | $11,266 | 29 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $7,335 | 38 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $7,127 | 45 | $0 (2020) |
| Lilly USA, LLC | $4,728 | 46 | $0 (2019) |
| AbbVie Inc. | $1,300 | 21 | $0 (2020) |
| Amgen Inc. | $760.11 | 33 | $0 (2021) |
| Insulet Corporation | $203.76 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,684 | 20 | Novo Nordisk Inc ($13,684) |
| 2023 | $19,989 | 31 | Novo Nordisk Inc ($19,842) |
| 2022 | $58,220 | 86 | Novo Nordisk Inc ($56,114) |
| 2021 | $27,024 | 44 | SANOFI-AVENTIS U.S. LLC ($16,298) |
| 2020 | $22,198 | 98 | Novo Nordisk Inc ($11,929) |
| 2019 | $49,550 | 130 | SANOFI-AVENTIS U.S. LLC ($27,813) |
| 2018 | $134,416 | 292 | SANOFI-AVENTIS U.S. LLC ($77,336) |
| 2017 | $112,529 | 320 | SANOFI-AVENTIS U.S. LLC ($81,981) |
All Payment Transactions
1,021 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
| 11/08/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
| 10/23/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 10/03/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 09/24/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
| 08/23/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
| 08/20/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 08/01/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| 06/26/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 06/24/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| 06/17/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
| 06/04/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
| 05/21/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 05/16/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 05/08/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 05/01/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 04/01/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,358.50 | General |
| Category: Diabetes | ||||||
| 03/18/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
| 03/14/2024 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
| 12/12/2023 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 12/08/2023 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 12/04/2023 | Novo Nordisk Inc | Ozempic (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 11/30/2023 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $580.00 | General |
| Category: Diabetes | ||||||
| 11/27/2023 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $725.00 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 178 | 247 | $70,360 | $21,245 |
| 2022 | 4 | 288 | 402 | $134,257 | $52,307 |
| 2021 | 7 | 306 | 467 | $78,840 | $36,167 |
| 2020 | 4 | 391 | 953 | $174,650 | $79,892 |
Total Patients
1,163
Total Services
2,069
Medicare Billing
$189,610
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 85 | $24,544 | $6,447 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $17,179 | $3,832 | 22.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 55 | $11,000 | $3,787 | 34.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 33 | $8,250 | $3,417 | 41.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 17 | $5,950 | $2,565 | 43.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 18 | $3,438 | $1,198 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 237 | $65,175 | $26,766 | 41.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 118 | 118 | $49,796 | $17,449 | 35.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 33 | 35 | $12,950 | $5,650 | 43.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $6,336 | $2,443 | 38.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 155 | 274 | $47,950 | $22,981 | 47.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 39 | 50 | $11,080 | $4,829 | 43.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 14 | 14 | $4,200 | $2,400 | 57.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $5,500 | $2,078 | 37.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 22 | 29 | $3,335 | $1,883 | 56.5% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 20 | 37 | $3,700 | $1,016 | 27.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 34 | 41 | $3,075 | $979.89 | 31.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 209 | 744 | $130,200 | $60,876 | 46.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 139 | 139 | $34,750 | $15,293 | 44.0% |
| 76536 | Ultrasound of head and neck | Office | 2020 | 26 | 27 | $5,400 | $2,490 | 46.1% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 17 | 43 | $4,300 | $1,233 | 28.7% |
About Dr. Samim Enayat, MD
Dr. Samim Enayat, MD is a Internal Medicine healthcare provider based in Fairfax, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1700053824.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samim Enayat, MD has received a total of $437,610 in payments from pharmaceutical and medical device companies, with $13,684 received in 2024. These payments were reported across 1,021 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($373,799).
As a Medicare-enrolled provider, Enayat has provided services to 1,163 Medicare beneficiaries, totaling 2,069 services with total Medicare billing of $189,610. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism|Endocrinology, Diabetes & Metabolism
- Location Fairfax, VA
- Active Since 05/08/2008
- Last Updated 01/10/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1700053824
Products in Payments
- SOLIQUA (Drug) $89,751
- TOUJEO (Drug) $73,373
- Ozempic (Drug) $62,381
- Rybelsus (Drug) $52,529
- JARDIANCE (Drug) $37,613
- SOLIQUA 100/33 (Drug) $20,829
- SOLIQUA 100/33 (Biological) $17,301
- RYBELSUS (Drug) $10,625
- Dexcom CGM (Device) $9,970
- TOUJEO (Biological) $7,594
- FARXIGA (Drug) $7,335
- INVOKANA (Drug) $7,055
- Tresiba (Drug) $5,962
- DISEASE STATE (Drug) $2,655
- Xultophy 100/3.6 (Drug) $1,916
- DEXCOM G6 CGM SYSTEM (Device) $1,060
- Androgel (Drug) $1,024
- Saxenda (Drug) $542.38
- Victoza (Drug) $541.90
- TRADJENTA (Drug) $321.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Fairfax
Brett Atwater, M.d, M.D
Internal Medicine — Payments: $355,531
Internal Medicine $355,531
Kathleen Harnden, M.d, M.D
Internal Medicine — Payments: $173,063
Internal Medicine $173,063
Dr. Daniel Kim, M.d., M.b.a, M.D., M.B.A
Internal Medicine — Payments: $124,814
Internal Medicine $124,814
Dr. Reza Zonozi, M.d, M.D
Internal Medicine — Payments: $118,319
Internal Medicine $118,319
Dr. Elizabeth Held, M.d, M.D
Internal Medicine — Payments: $84,557
Internal Medicine $84,557
Sekwon Jang, M.d, M.D
Internal Medicine — Payments: $75,808
Internal Medicine $75,808